Overview
Hybrigenics Services offers fee-for-service R&D support with proprietary ULTImate Y2H platforms for protein-protein, drug-protein interaction studies, and target identification in drug discovery. They provide custom synthetic VHH nanobody selection, validation, and affinity maturation using their Hybribody library, animal-free process. Services extend to fundamental research, agrosciences, and partnerships with pharma, biotechs, and academia across therapeutic areas like oncology.
Frequently asked questions
- What are your core technological platforms?
- ULTImate Y2H for comprehensive protein interaction screening including drug-protein targets via patented cell-to-cell mating, and Hybribody for synthetic VHH nanobody selection, validation, and affinity maturation.
- Which industries and therapeutic areas do you serve?
- Pharma, biotechs, startups, agrosciences, and academia in oncology, cardiology, neurology, and plant biology for sustainable research.
- What is your experience with regulatory or drug discovery needs?
- Specialized Y2H adapted for drug discovery to identify direct compound targets; collaborations like with Servier for DUB target validation in oncology and other fields.